Table 1.
Subject demographics and lung function
| Healthy Never-Smokers (n = 17) |
Asymptomatic Smokers (n = 15) |
COPD (n = 16) |
|
|---|---|---|---|
| Male/Female | 9/8 | 6/9 | 7/9 |
| Age [y] | 64 ± 6 | 62 ± 3 | 67 ± 7 |
| Weight [kg] | 76 ± 14 | 76 ± 12 | 72 ± 13 |
| Height [cm] | 173 ± 9 | 169 ± 9 | 170 ± 9 |
| FEV1%pred | 110 ± 15 | 109 ± 13 | 61 ± 23*** |
| VC %pred | 109 ± 20 | 112 ± 13 | 107 ± 18 |
| FEV1/VC %pred | 78.6 ± 4.0 | 78.4 ± 5.6 | 44.9 ± 14.2*** |
| DL,CO %pred | 92.0 ± 10 | 88.2 ± 13 | 60.2 ± 22***† |
| GOLD-stage (1/2/3/4) | 3/7/5/1 |
† Data for DL,CO for one subject in the COPD group is missing
***Significance < 0.001 level
Descriptive demographic data (average ± 1 standard deviation) for the subjects, lung function tests performed post bronchodilation, 1.5 mg terbutaline (Bricanyl Turbuhaler, Astra Zeneca, Mölndal, Sweden)